Toth Financial Advisory Corp Makes New Investment in Mirum Pharmaceuticals, Inc. $MIRM

Toth Financial Advisory Corp purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 10,285 shares of the company’s stock, valued at approximately $1,204,000.

Other large investors have also modified their holdings of the company. Nan Fung Trinity HK Ltd. increased its holdings in Mirum Pharmaceuticals by 45.6% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock valued at $17,969,000 after buying an additional 71,214 shares during the period. BlackRock Inc. bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter worth about $513,945,000. Emerald Advisers LLC lifted its holdings in shares of Mirum Pharmaceuticals by 8.2% during the 1st quarter. Emerald Advisers LLC now owns 397,263 shares of the company’s stock worth $36,699,000 after acquiring an additional 30,129 shares during the period. SBI Okasan Asset Management Co.Ltd. acquired a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $1,283,000. Finally, Rice Hall James & Associates LLC bought a new stake in Mirum Pharmaceuticals in the second quarter valued at about $12,956,000.

Mirum Pharmaceuticals Trading Down 2.3%

MIRM stock opened at $97.46 on Friday. The business has a fifty day moving average price of $110.63 and a 200 day moving average price of $101.79. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The stock has a market capitalization of $6.33 billion, a price-to-earnings ratio of -6.70 and a beta of 0.52. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. During the same period in the prior year, the firm posted ($0.12) EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 37.9% compared to the same quarter last year. Analysts expect that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Analyst Ratings Changes

MIRM has been the topic of several analyst reports. Raymond James Financial reiterated a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Wall Street Zen upgraded Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Wolfe Research assumed coverage on Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target on the stock. TD Cowen dropped their price objective on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, UBS Group set a $137.00 price objective on Mirum Pharmaceuticals in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $137.31.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the sale, the senior vice president owned 1,274 shares in the company, valued at approximately $127,400. This trade represents a 96.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher Peetz sold 20,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $98.92, for a total transaction of $1,978,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $19,221,046.28. This represents a 9.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 133,156 shares of company stock valued at $13,763,562 in the last 90 days. 8.32% of the stock is currently owned by insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.